Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis

被引:74
作者
Montano-Loza, Aldo J. [2 ]
Carpenter, Herschel A. [1 ]
Czaja, Albert J. [2 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Gastroenterol, Rochester, MN 55905 USA
关键词
D O I
10.1111/j.1572-0241.2008.01922.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: Hepatocellular carcinoma (HCC) is an uncommon but serious occurrence in autoimmune hepatitis. Our objective was to determine predictors for this neoplasm to improve screening strategies. METHODS: Two hundred twenty-seven patients underwent hepatic ultrasonography and serum alpha fetoprotein determinations at 6-12-month intervals. RESULTS: Nine patients developed HCC (4%), and each had cirrhosis >= 73 months prior to the malignancy (mean, 110 +/- 7 months). By univariate Cox analysis, features at accession associated with a higher risk of HCC were: male gender (Hazard Ratio [HR] 7.0, 95% Confidence Interval [CI] 1.87-26.1, P = 0.004), history of blood transfusion (HR 5.6, 95% CI 1.51-21.1, P = 0.01), thrombocytopenia (HR 7.3, 95% CI 1.89-28.3, P = 0.004), ascites (HR 23.8, 95% CI 4.65-121.8, P = 0.0001), esophageal varices (HR 7.9, 95% CI 1.96-31.8, P = 0.004), and any sign of portal hypertension (HR 19.1, 95% CI 3.91-93.3, P = 0.0003). Features after accession associated with a higher risk of malignancy were: treatment for >= 3 yr (HR 7.6, 95% CI 1.25-18.2, P = 0.02), worsening laboratory tests during corticosteroid therapy (HR 7.6, 95% CI 1.81-32.1, P = 0.006), and cirrhosis for >= 10 yr (HR 8.4, 95% CI 1.69-41.9, P = 0.009). CONCLUSIONS: Male gender, features of portal hypertension, history of blood transfusions, immunosuppressive treatment for >= 3 yr, treatment failure, and cirrhosis of >= 10 yr duration identify patients at risk for HCC. These risk factors should focus screening in autoimmune hepatitis.
引用
收藏
页码:1944 / 1951
页数:8
相关论文
共 57 条
[1]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[2]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]   THE RISK OF DETERMINING RISK WITH MULTIVARIABLE MODELS [J].
CONCATO, J ;
FEINSTEIN, AR ;
HOLFORD, TR .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :201-210
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
Czaja AJ, 1997, HEPATOLOGY, V25, P317
[7]  
Czaja AJ, 1996, HEPATOLOGY, V24, P1068
[8]   SIGNIFICANCE OF HLA DR4 IN TYPE-1 AUTOIMMUNE HEPATITIS [J].
CZAJA, AJ ;
CARPENTER, HA ;
SANTRACH, PJ ;
MOORE, SB .
GASTROENTEROLOGY, 1993, 105 (05) :1502-1507
[9]   Diagnosis and treatment of autoimmune hepatitis [J].
Czaja, AJ ;
Freesel, DK .
HEPATOLOGY, 2002, 36 (02) :479-497
[10]   FREQUENCY AND SIGNIFICANCE OF ANTIBODIES TO LIVER KIDNEY MICROSOME TYPE-1 IN ADULTS WITH CHRONIC ACTIVE HEPATITIS [J].
CZAJA, AJ ;
MANNS, MP ;
HOMBURGER, HA .
GASTROENTEROLOGY, 1992, 103 (04) :1290-1295